Georgina Long
Melanoma Institute Australia · Medical oncologist/researcher
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Georgina Long as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:38 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06999980 · Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)Melanoma Institute Australia · recruiting · Cutaneous Melanoma, Mucosal Melanoma · study chair
- Ph2NCT05545969 · Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal MelanomaMelanoma Institute Australia · withdrawn · Mucosal Melanoma · principal investigator
- Ph2NCT05418972 · A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous MelanomaMelanoma Institute Australia · active not recruiting · Stage II Melanoma · principal investigator
- Ph3NCT04949113 · Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III MelanomaThe Netherlands Cancer Institute · active not recruiting · Malignant Melanoma Stage III · study chair
- Ph1/Ph2NCT04834973 · A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanomaQBiotics Group Limited · terminated · Melanoma · principal investigator
- Ph2NCT02374242 · Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain MetastasesMelanoma Institute Australia · active not recruiting · Melanoma, Brain Metastases · study chair
- Ph2NCT01972347 · Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive MelanomaMelanoma Institute Australia · completed · Melanoma · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:38 UTC. The ranking covers the 200 most relevant of 250 PubMed records, and a shared surname and initials can bring in a namesake. All 250 on PubMed
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.N Engl J Med · 20156,463 citationsRCR 203.2
- Pembrolizumab versus Ipilimumab in Advanced Melanoma.N Engl J Med · 20154,791 citationsRCR 149.2
- Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med · 20154,573 citationsRCR 142.4
- 3,015 citationsRCR 114.3
- 2,979 citationsRCR 97.1
- Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.N Engl J Med · 20122,244 citationsRCR 58.2
- 2,142 citationsRCR 66.8
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.N Engl J Med · 20171,847 citationsRCR 59.7
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.N Engl J Med · 20221,652 citationsRCR 113.5
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.N Engl J Med · 20181,569 citationsRCR 53.2